The interaction between advanced glycation end products (AGEs) and the cellular receptor of AGE (RAGE) could result in cellular activation and imflammation (1). In vitro and in vivo studies indicate that RAGE plays a important role in the pathogenesis of diabetic vascular complications (2). It is plausible that genetic differences in the RAGE gene could alter expression and function to affect disease development. Many polymorphisms in the RAGE gene have already been identified (3) and show no association with macro- or microvasculopathy of diabetes (4,5). However, Hudson et al. (6) have detected two polymorphisms, −429T/C and −374T/A, in RAGE gene promoters. They reported that the −429T/C polymorphism is associated with diabetic retinopathy in type 2 diabetic patients, but found no association between the two polymorphisms and macrovascular diseases (7).

We screened the −429T/C and −374T/A polymorphisms among 212 unrelated Chinese nondiabetic subjects and 357 type 2 diabetic subjects (205 with and 152 without diabetic retinopathy). Type 2 diabetes was diagnosed according to 1999 World Health Organization criteria. Retinopathy was defined by an opthamologist. Genotyping was performed by PCR fragment-length polymorphism assay. Primers were designed according to the method of Hudson et al. (6).

There were no differences in allele frequencies between diabetic subjects with (−429T 90.1%, C 9.9%; −374T 86.4%, A 13.6%) or without (−429T 87.8%, 12.2%; −374T 87.3%, 12.7) diabetic retinopathy. No differences were found between the diabetic and nondiabetic subjects (−429T 87.3%, 12.7%; −374T 86.1%, 13.9%). The −429C and −374A allele frequencies (12.7 and 13.9%, respectively) are lower than those in Caucasians (18 and 20%) (7).

Our study indicates that the −429T/C and −374T/A polymorphisms in RAGE gene promoters are not associated with diabetic retinopathy in Chinese patients with type 2 diabetes. However, further studies on large populations are still required to evaluate whether these polymorphisms and other polymorphisms in RAGE genes are related to diabetic vascular complications.

1
Schmidt AM, Yan SD, Wautier JL, Stern D: Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis.
Circ Res
84
:
489
–497,
1999
2
Schmidt AM, Stern D: RAGE: a new target for the prevention and treatment of the vascular and imflammatory complications of diabetes.
Trends Endocrinol Metab
11
:
368
–375,
2000
3
Hudson BI, Stickland MH, Grant PJ: Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene: prevalence in type 2 diabetes and ethnic groups.
Diabetes
47
:
1155
–1157,
1998
4
Liu L, Xiang K: RAGE Gly82Ser polymorphism in diabetic microangiopathy (Letter).
Diabetes Care
22
:
646
,
1999
5
Kankova K, Beranek M, Hajek D, Vlknova E: Polymorphisms 1704G/T, 2184A/G, and 2245G/A in the RAGE gene are not associated with diabetic retinopathy in NIDDM pilot study.
Retina
22
:
119
–121,
2002
6
Hudson BI, Stickland MH, Futers TS, Grant PJ: Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy.
Diabetes
50
:
1505
–1511,
2001
7
Hudson BI, Stickland MH, Futers TS, Grant PJ: Study of the −429T/C and −374T/A receptor for advanced glycation end products promoter polymorphisms in diabetic and nondiabetic subjects with macrovascular disease (Letter).
Diabetes Care
24
:
2004
,
2001